Ipamorelin

Selective Growth Hormone Secretagogue

Ipamorelin is a growth hormone releasing peptide that stimulates the pituitary gland to produce more growth hormone. What makes it special is its selectivity. Unlike older peptides in this class, ipamorelin increases growth hormone without affecting cortisol, prolactin, or other hormones that cause unwanted side effects. Its growth hormone release is comparable to other ghrelin agonists, but it does not significantly raise cortisol, prolactin, or ACTH. It causes minimal appetite stimulation, and its side effect profile is very clean.

There are older peptides in this family, such as GHRP-2 and GHRP-6, which also work on ghrelin receptors, but they come with baggage. They spike cortisol (the stress hormone) and prolactin (which can cause unwanted side effects like low libido or breast tissue changes in men). Those peptides also make people ravenously hungry, which is not ideal if the goal is fat loss. Ipamorelin is different. It is selective. You get the growth hormone pulse without all the messy hormonal side effects. This is exactly why ipamorelin has become the go-to peptide when it comes to stacking with CJC.

The peptide was developed by Novo Nordisk in Denmark and has been called the first selective growth hormone secretagogue. It is a pentapeptide, meaning it contains just five amino acids. Despite its small size, it produces significant growth hormone release with a favorable side effect profile.

Ipamorelin works by mimicking ghrelin, the hunger hormone. It binds to ghrelin receptors in the pituitary gland and triggers growth hormone release. The key difference from natural ghrelin is that ipamorelin does not strongly stimulate appetite the way ghrelin does, and it does not cause the cortisol and prolactin spikes seen with other growth hormone releasing peptides.

This peptide is not FDA-approved. It reached Phase 2 clinical trials for postoperative ileus (gut motility after surgery) but did not meet endpoints, and development was discontinued. It remains available through peptide suppliers for research purposes.

How It Works

Ipamorelin belongs to a class of compounds called growth hormone secretagogues. These compounds stimulate growth hormone release through the ghrelin receptor pathway, which is different from the GHRH (growth hormone releasing hormone) pathway.

The Ghrelin Receptor

The stomach produces a hormone called ghrelin. Ghrelin has several functions: it triggers hunger, influences energy balance, and signals the pituitary gland to release growth hormone. The receptor that ghrelin binds to is called GHS-R1a (growth hormone secretagogue receptor type 1a).

Ipamorelin binds to this same receptor. When it does, the pituitary releases growth hormone. But ipamorelin is highly selective. In studies, even at doses 200 times higher than needed for growth hormone release, it did not increase ACTH (which leads to cortisol) or prolactin. This selectivity is what sets it apart from GHRP-2 and GHRP-6, which do increase those hormones.

The Growth Hormone Pulse

Ipamorelin creates a rapid spike in growth hormone. After injection, growth hormone levels peak at about 40 minutes and then decline back to baseline. The half-life of ipamorelin is approximately 2 hours. This means the effect is quick and temporary, which actually mimics how the body naturally releases growth hormone in pulses.

This pulsatile pattern is considered healthier than sustained elevation because it reflects how the body normally operates. You get the growth hormone boost without overriding natural feedback systems.

Downstream Effects

The growth hormone released by ipamorelin travels to the liver and stimulates production of IGF-1 (insulin-like growth factor 1). IGF-1 is responsible for many of the anabolic effects: muscle protein synthesis, cellular repair, fat metabolism, and tissue growth. Higher IGF-1 levels over time lead to improvements in body composition, recovery, and overall vitality.

Benefits

Growth Hormone Release Without Side Effects

Ipamorelin increases growth hormone without raising cortisol, prolactin, or other stress hormones. This is the primary advantage over older peptides like GHRP-6. Elevated cortisol interferes with muscle building and promotes fat storage. Elevated prolactin can cause sexual dysfunction and other issues. Ipamorelin avoids both.

Improved Body Composition

Higher growth hormone and IGF-1 levels support muscle growth and fat loss. Users typically report an improved ability to build lean mass, reduced body fat (especially around the

midsection), and better overall body composition. These effects develop gradually over weeks to months of consistent use.

Faster Recovery

Growth hormone accelerates tissue repair. This translates to faster recovery between training sessions, reduced muscle soreness, and improved healing from minor injuries. Athletes and fitness enthusiasts often use ipamorelin specifically for this benefit.

Better Sleep

Growth hormone release naturally peaks during deep sleep. Ipamorelin, especially when taken before bed, enhances this process. Users commonly report falling asleep faster, sleeping more deeply, and waking up feeling more refreshed.

Joint and Connective Tissue Health

IGF-1 stimulates collagen synthesis. Over time, this can improve joint comfort, skin quality, and overall connective tissue health. These effects take longer to notice than changes in body composition, typically appearing after 2 to 3 months of use.

Bone Health

Ipamorelin has been studied specifically for its effects on bone. Research shows it can counteract bone loss caused by glucocorticoid medications and increase bone formation markers. This makes it relevant for long-term health, especially in aging populations.

Mild Appetite Effects

Although ipamorelin activates ghrelin receptors, its effect on hunger is much milder than GHRP- 6. Some users notice increased appetite, which can be helpful for those trying to eat more for muscle gain. Others notice minimal appetite change.

What the Science Shows

Ipamorelin has been studied in animal models, healthy human volunteers, and clinical trials for specific medical conditions.

Selectivity Study – Raun et al. (1998)

Published in the European Journal of Endocrinology. This landmark study established ipamorelin as the first selective growth hormone secretagogue.

• Ipamorelin released growth hormone with potency and efficacy similar to GHRP-6
• Unlike GHRP-6 and GHRP-2, ipamorelin did not increase ACTH or cortisol
• This selectivity held even at doses more than 200 times higher than the effective dose for

GH release

• No effect on FSH, LH, prolactin, or TSH

The researchers concluded that ipamorelin was the first GHRP receptor agonist with selectivity for GH release similar to natural GHRH.

Human Pharmacokinetics – Gobburu et al. (1999)

Published in Pharmaceutical Research. Dose escalation study in 40 healthy male volunteers.

• Half-life of approximately 2 hours
• Growth hormone peaked at 0.67 hours (40 minutes) after injection
• Dose-dependent response across all tested doses
• Exponential decline to baseline
• Well tolerated

Bone Studies – Andersen et al. (2001)

Studied ipamorelin’s effects on bone formation in rats treated with glucocorticoids (which cause bone loss).

• Ipamorelin counteracted the glucocorticoid-induced decrease in bone formation
• Increased bone formation rate by up to fourfold
• Improved bone mineral content

Bone Growth Study – Johansen et al. (1999)

Published in Growth Hormone & IGF Research. Studied longitudinal bone growth in adult female rats.

• Dose-dependent increase in bone growth rate from 42 μm/day to 52 μm/day
• Pronounced dose-dependent effect on body weight gain
• Pituitary GH content remained unchanged (no suppression)

Postoperative Ileus Trials – Beck et al. (2008)

A 2008 trial with 114 patients undergoing bowel resection found that ipamorelin did not significantly reduce time to first meal compared to placebo. However, patients undergoing open surgery showed faster return of GI function compared to historical data. Development was discontinued after these results.

Dosing Protocol

Ipamorelin is typically dosed 1 to 3 times daily via subcutaneous injection. It works best when combined with a GHRH peptide like CJC-1295 without DAC.

Standard Solo Protocol

Dose Frequency Timing Schedule Cycle Length

200–300 mcg 1–2x daily Before bed and/or Daily 8–12 weeks morning (fasted)

Combined with CJC-1295 (Preferred)

Ipamorelin CJC-1295 (no Frequency Timing Cycle Length DAC)

100–250 mcg 100–250 mcg Once daily Before bed 8–12 weeks

The combination produces significantly more growth hormone release than either peptide alone. The GHRH signal (CJC-1295) and the ghrelin signal (ipamorelin) work through different pathways and amplify each other.

Split Dosing Protocol

For maximum GH pulsatility:

• Morning (fasted): 100–250 mcg ipamorelin + 100–250 mcg CJC-1295
• Before bed: 100–250 mcg ipamorelin + 100–250 mcg CJC-1295

This creates two separate growth hormone pulses per day.

Dosing by Body Weight

Body Weight Dose per Injection

Under 150 lbs 100–150 mcg

150–200 lbs 150–200 mcg

Over 200 lbs 200–300 mcg

Important Dosing Notes

• Take on an empty stomach, at least 2 hours after eating. Food, especially carbohydrates,

raises insulin and blunts growth hormone release.

• Wait at least 30 minutes after injection before eating.
• Daily dosing is recommended. Research supports continuous use for up to 16 weeks

followed by 4 weeks off to address chronic desensitization.

• A standard cycle of 12 to 16 weeks on followed by 4 weeks off is commonly used.

Draw Volumes by Vial Size

5 mg Vial (2 mL reconstitution = 2.5 mg/mL)

Dose Volume Units on Syringe

100 mcg 0.04 mL 4 units

150 mcg 0.06 mL 6 units

200 mcg 0.08 mL 8 units

250 mcg 0.10 mL 10 units

300 mcg 0.12 mL 12 units

Vial duration at 200 mcg/day: approximately 3.5 weeks.

5 mg Vial (1 mL reconstitution = 5 mg/mL)

Dose Volume Units on Syringe

100 mcg 0.02 mL 2 units

150 mcg 0.03 mL 3 units

200 mcg 0.04 mL 4 units

250 mcg 0.05 mL 5 units

300 mcg 0.06 mL 6 units

Note: Very small volumes may be difficult to measure accurately. Consider 2 mL reconstitution for easier dosing.

10 mg Vial (2 mL reconstitution = 5 mg/mL)

Dose Volume Units on Syringe

100 mcg 0.02 mL 2 units

150 mcg 0.03 mL 3 units

200 mcg 0.04 mL 4 units

250 mcg 0.05 mL 5 units

300 mcg 0.06 mL 6 units

Vial duration at 200 mcg/day: approximately 7 weeks.

Reconstitution Instructions

Materials Needed:

• Peptide vial (lyophilized powder)
• Bacteriostatic water
• Sterile syringe for reconstitution
• Alcohol swabs

Instructions: 1. Wipe the vial stopper and bacteriostatic water vial with alcohol swabs. 2. Draw 1 to 2 mL of bacteriostatic water. 3. Insert the needle through the rubber stopper at an angle. 4. Let the water trickle down the inside wall of the vial slowly. 5. Do not inject directly onto the powder. 6. Swirl gently until fully dissolved (do not shake). 7. The solution should be clear. If cloudy or if it contains particles, do not use.

Side Effects and Cautions

Ipamorelin has one of the best side effect profiles of any growth hormone releasing peptide because it does not affect cortisol or prolactin.

Common Side Effects (Usually Mild and Transient)

• Injection site redness or irritation
• Mild flushing
• Mild water retention
• Tingling or numbness (usually in the hands; resolves quickly)
• Increased hunger (much milder than GHRP-6)
• Head rush or lightheadedness (especially at higher doses)
• Headache

Uncommon Side Effects

• Fatigue during initial adaptation
• Vivid dreams

What You Will Not See (Compared to Other GHRPs)

• Significant cortisol increase
• Prolactin increase
• Intense hunger spikes

The lack of cortisol and prolactin effects is the main advantage of ipamorelin. Side effects that do occur tend to resolve within the first 1 to 2 weeks of use.

Contraindications and Precautions

Do Not Use If You Have

• Active cancer or a history of cancer
• Diabetic retinopathy
• Pregnancy or breastfeeding

Use with Caution

• Diabetes or prediabetes (monitor blood sugar)
• Cardiovascular disease
• History of carpal tunnel syndrome

Drug Interactions

Growth hormone can affect insulin sensitivity. If using insulin or diabetes medications, blood sugar management may change. Glucocorticoids may blunt the growth hormone response.

Comparison to Other Growth Hormone Releasing Peptides

Peptide GH Release Cortisol Prolactin Hunger Half-Life

Ipamorelin Strong None None Mild ~2 hours

GHRP-2 Strong Increases Increases Moderate ~30 min

GHRP-6 Strong Increases Increases Strong ~20 min

Hexarelin Strongest Increases Increases Moderate ~30 min

MK-677 Strong None None Strong 24+ hours

Ipamorelin is the most selective injectable option. If you want growth hormone release without affecting other hormones, it is the clear choice. MK-677 is oral but has a broader side effect

profile. It can affect insulin sensitivity and blood glucose and causes much stronger appetite stimulation. It is also not a peptide—it is a nonpeptide ghrelin mimetic.

Success Tips

Combine with CJC-1295

Ipamorelin works well alone, but it works significantly better when combined with a GHRH peptide. CJC-1295 without DAC is the most common pairing. The synergy between the two pathways produces 3 to 5 times more growth hormone than either alone.

Time It Right

Inject on an empty stomach. The ideal times are first thing in the morning (fasted) or 2 to 3 hours after dinner before bed. Food intake blunts the GH response.

Before Bed Is Best

If you can only inject once daily, do it before bed. Growth hormone naturally peaks during deep sleep. Pre-bed dosing enhances this natural process and can improve sleep quality.

Be Patient

Changes happen gradually. Improved sleep and recovery may be noticeable within 1 to 2 weeks. Body composition changes typically become visible at 6 to 8 weeks. Full effects develop over months.

Support with Training and Nutrition

Ipamorelin gives you the tools for better body composition. You still need to train hard and eat right to see results. Resistance training 3 to 4 times per week and adequate protein (0.8 to 1.0 grams per pound of body weight) are essential.

Storage and Handling

Before Reconstitution

• Store lyophilized (powder) vials in the freezer at −20°C (−4°F)
• Can also be stored in the refrigerator at 2°C to 8°C (36°F to 46°F)
• Protect from light
• Do not use past the expiration date

After Reconstitution

• Refrigerate at 2°C to 8°C (36°F to 46°F)
• Use within 14 to 28 days
• Do not freeze after reconstitution
• Keep the stopper clean
• If the solution becomes cloudy or contains particles, discard it

Legal Status

United States: Ipamorelin is not FDA-approved for any medical use. It is classified as a research chemical.

WADA Status: Ipamorelin is prohibited at all times as a growth hormone secretagogue under World Anti-Doping Agency rules.

Competitive Athletes: Do not use if subject to drug testing.

Product Source

Ipamorelin is available as a research peptide from qualified peptide suppliers. When sourcing research-grade ipamorelin, ensure the supplier provides third-party testing, certificates of analysis (COA), and proper documentation of purity (typically ≥98%). Ipamorelin is commonly sold alongside CJC-1295 without DAC for combination protocols. Always verify the legitimacy and quality standards of any peptide supplier.

Frequently Asked Questions

Why is ipamorelin better than GHRP-6? Selectivity. Ipamorelin releases growth hormone without increasing cortisol or prolactin. GHRP- 6 increases both, which can interfere with muscle building and cause other side effects. GHRP-6 also causes intense hunger spikes that many users find uncomfortable.

Can I use ipamorelin alone? Yes, but you will get better results combining it with CJC-1295 without DAC. The two peptides work through different pathways and amplify each other’s effects.

How long until I see results? Sleep improvements often appear within 1 to 2 weeks. Body composition changes typically become noticeable at 6 to 8 weeks. Full effects develop over 3 to 6 months.

Will ipamorelin make me hungry? It may increase appetite mildly, but nothing like GHRP-6. Many users notice minimal hunger change. Some find the mild appetite increase helpful for eating enough to support muscle growth.

Is ipamorelin safe for long-term use? Ipamorelin has a favorable safety profile with no significant effects on cortisol or prolactin. Daily dosing works well for most people. Research on chronic desensitization shows it develops around 16 weeks of continuous use and fully reverses after 4 weeks off. A standard cycle of 12 to 16 weeks on followed by 4 weeks off addresses this based on human data.

Does ipamorelin suppress natural growth hormone? Ipamorelin stimulates the pituitary to produce its own growth hormone. It does not replace the hormone. This is different from synthetic HGH injections, which can suppress natural production. Most evidence suggests pituitary function remains intact with proper use.

What is the difference between ipamorelin and MK-677? MK-677 (also called ibutamoren) is not actually a peptide. It is a nonpeptide ghrelin mimetic that works on the same pathway. The main differences: ipamorelin is injectable with a 2-hour half- life, creating natural pulses. MK-677 is oral with a 24+ hour duration, creating sustained elevation rather than a natural pulse pattern. MK-677 has a broader side effect profile, including significant appetite stimulation, potential effects on insulin sensitivity and blood glucose, and cortisol elevation. The convenience of oral dosing comes with trade-offs. If you want the cleanest option, ipamorelin is the choice. If you cannot or will not inject, MK-677 is an option, but understand what you are trading.

References

8. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552–561. 9. Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999;16(9):1412–1416. 10. Andersen NB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Hormone & IGF Research. 2001;11(5):266–272. 11. Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106–113.

12. Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25–37. 13. Svensson J, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Journal of Endocrinology. 2000;165(3):569– 577.